within Pharmacolibrary.Drugs.ATC.A;

model A07DA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.00013333333333333334,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07DA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Loperamide oxide is the N-oxide metabolite and prodrug of loperamide, which is a synthetic opioid used primarily as an anti-diarrheal agent. Loperamide oxide was developed to reduce central nervous system penetration compared to loperamide and is not approved for current clinical use.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters for loperamide oxide in humans found in published literature. The following values are estimated based on its classification as a prodrug of loperamide and general properties of oral opioid receptor agonists used for local gut activity.</p><h4>References</h4><ol><li><p>Matheson, AJ, &amp; Noble, S (2000). Racecadotril. <i>Drugs</i> 59(4) 829–837. DOI:<a href=\"https://doi.org/10.2165/00003495-200059040-00010\">10.2165/00003495-200059040-00010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10804038/\">https://pubmed.ncbi.nlm.nih.gov/10804038</a></p></li><li><p>Kamali, F, &amp; Huang, ML (1996). Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole. <i>British journal of clinical pharmacology</i> 41(2) 125–128. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1996.tb00169.x\">10.1111/j.1365-2125.1996.tb00169.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8838438/\">https://pubmed.ncbi.nlm.nih.gov/8838438</a></p></li><li><p>Van Beijsterveldt, LE, et al., &amp; Heykants, JJ (1995). Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 23(2) 216–222. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7736914/\">https://pubmed.ncbi.nlm.nih.gov/7736914</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07DA05;
